Health Benefits of Lowering Sodium Intake in the US
|
|
|
- Brett Harper
- 5 years ago
- Views:
Transcription
1 Health Benefits of Lowering Sodium Intake in the US Lawrence J Appel, MD, MPH Professor of Medicine, Epidemiology and International Health (Human Nutrition) Director, Welch Center for Prevention, Epidemiology and Clinical Research The Johns Hopkins University Dec 5, 2012
2 Research Disclosure McCormick Foundation
3 Outline Benefits of Lowering Sodium Intake Methodological Challenges Measurement of blood pressure Measurement of sodium Intake Cohort studies
4 Worldwide, Elevated BP is the Leading Cause of Preventable Deaths Global health risks: WHO, 12/09
5 Critical Facts: (1) Magnitude of the BP Epidemic 54% of strokes and 47% of coronary heart disease events attributed to elevated BP 1 26% of adults worldwide (971 million) have hypertension 2 Lifetime risk 3 of developing hypertension is 90% 1 Lawes CM Lancet 2008;371: Kearney Lancet 2005;305:217 3 Vasan JAMA 2002; 287:1003
6 mm Hg Mean Systolic BP Rises with Age (U.S. Women) SBP Rise with Age = ~0.6 mmhg per year Black White Mexican-American Burt, Hypertension 1995;26:60. Age
7 Critical Facts: (2) Costs of the BP Epidemic Projected direct (medical) costs of CVD in 2030 in billions All CVD $818b Hypertension $200b CHD $106b Heart Failure $77b Stroke $95b [Hypertension as risk factor] $389b Heidenreich PA.Circulation. 2011;123:933-44
8 Types of Evidence Linking Sodium Intake to Blood Pressure Epidemiology Migration Genetic Animal Trials Population Interventions Over 50 population studies Several, e.g. Kenya All defects identified so far impair the ability of the kidney to excrete salt. All forms of hypertension are caused or aggravated by salt No study has documented increased CVD risk from reduced sodium Children: ~10 trials, one trial in infants Adults: > 50 trials, 10 dose-response Northern Japan Finland Portuguese villages
9 As Sodium Intake Is Reduced, So is Blood Pressure Typical Diet Systolic Blood Pressure 8.9 mmhg from low Na +DASH -6.7 p< P<.0001 DASH Diet 1,500 2,400 3,300 Sodium Level: mg/d per day Sacks, NEJM 2001;344:3
10 Factors Associated with Greater BP Reduction from Lower Sodium Intake Fixed factors African-Americans Middle and older-aged persons Genetic Factors Individuals with: Hypertension Diabetes Chronic Renal Insufficiency Modifiable Low potassium intake Poor quality diet
11 Recommended Upper Limits Upper Limits for: General High Risk* % of US Adults 52% 48%** Sodium (mg) 2,300 1,500 Sodium (mmol) Salt (g), [Sodium Chloride] *African-Americans, Adults > 51 yrs, Hypertensives, and Diabetics **MMWR 2011, Vol 60, No. 41
12 Reduced Sodium Intake Has Greater BP Effects in African-Americans African-Americans Non-African-Americans 0 P-interaction < 0.05 Vollmer, Ann Int Med 2001;135:1019
13 Reduced Sodium Intake Has Greater BP Effects in Hypertensives Hypertensives Non-Hypertensives 0 P-interaction < 0.05 Vollmer, Ann Int Med 2001;135:1019
14 Dose Response Trial in Hypertensives SBP (mm Hg) DBP (mm Hg) * +8* +4* +5* 1.1 (50) 2.3 (100) 4.6 (200) grams/day (mmol/day) MacGregor, 1989 (20 hypertensive)
15 Reduced Sodium Intake Has Greater BP Effects in Middle- and Older-Aged Persons than Younger Persons Age > 45 Age < * P-interaction < 0.05 Vollmer, Ann Int Med 2001;135:1019
16 Dose Response in Elderly with Isolated Systolic Hypertension SBP (mmhg) DBP (mmhg) P <0.01* 0.01 P <0.05* 0.92 (40) 2.1(90) 3.2(140) 5.5 (240) 7.8 (340) grams/day (mmol/day) Johnson, 2001 (n=15 elderly with isolated systolic hypertension)
17 Trials of Sodium Reduction in Patients with Diabetes 13 trials with 254 individuals 75 individuals with type 1 diabetes 158 individuals with type 2 diabetes Duration median: 1 week, range: 5 days to 12 wks * Suckling RJ, Cochrane Review, 2010 Dec 8;(12):CD006763
18 BP Reductions from Lowering Sodium Intake: Diabetes Type 1 DM Type 2 DM SBP (mmhg) DBP (mmhg) Median Na (mg/d) Reduction 4,700 2,900 * Suckling RJ, Cochrane Review, 2010 Dec 8;(12):CD006763
19 Estimated BP Reductions from Lowering Sodium Intake SBP (mmhg) DBP (mmhg) Na (mg/d) Reduction Children 1 Non-HTN 2 HTN 2 HTN 3 Resistant n/a 1,700 1,800 2,300 1 He,HTN 2006;48:861 2 Cochrane Review, 2006; 3 Pimenta, HTN 2009;54:475
20 Population-Based Strategy SBP Distributions After Intervention Before Intervention Reduction in BP Stamler R. Hypertension 1991;17:I-16 I-20. Reduction in SBP mmhg % Reduction in Mortality Stroke CHD Total
21 Estimated Annual Number of Prevented Heart Attacks from Population-Wide Sodium Reduction Bibbins-Domingo, NEJM 2010;362:590
22 Estimated Annual Number of Prevented Heart Attacks from Population-Wide Sodium Reduction Bibbins-Domingo, NEJM 2010;362:590
23 Sodium Reduction Lowers CVD Risk: Meta-Analysis of Trials Events Na/Cntl Trial TOHP I 17 / 32 TOHP II 71 / 80 Morgan 6 / 5 TONE 36 / 46 Total 130 / 163 He FJ, MacGregor GA. Lancet. 2011;378:
24 Methodological Issues
25 Blood Pressure: High Degree of Random Error (Noise) Huge within-person variability in blood pressure Reduced by: Standardized technique Multiple visits Multiple measurements (e.g. ambulatory BP) Implication: Impossible to classify individuals as salt sensitive
26 Distribution of Systolic BP Change in Non- Hypertensive Adults (Pre-Post) in Response to Reduced Sodium Intake Miller, J Chronic Dis 40, 1987
27 Percent of Participants Distribution of Systolic BP Differences Between Two Periods When Participants Ate the Same Diet/Same Sodium Obarzanek, HTN 2003;42:459 SBP Change (mmhg)
28 Percent of Participants Distribution of Systolic BP Differences Between Two Periods with Different Sodium 35 Levels (~ 70 mmol/d) SBP Change (mmhg) Obarzanek, HTN 2003;42:459
29 Major Methodological Challenges in Observational Studies that Relate Sodium Intake to CVD Random error in sodium assessment Systematic error in sodium assessment Potential for reverse causality Major analytic issue, e.g. under-adjustment Potential for residual confounding 26 studies with 31 independent samples On average, 2.5 issues/study
30
31 Random and Systematic Error in Measuring Na Intake Random error Reason: high day-to-day variability of Na within an individual Impact: bias to the null Systematic error Reason: underreporting of intake from 24 hr recalls OR incomplete urine collection Impact: potential for paradoxical relationship Both types of errors extremely common
32 Measurement of Na Intake Optimal Multiple, high quality 24 hour urine collections Suboptimal 24 hour urine collected with limited or no attention to quality control Spot, overnight or timed urines 24 hour dietary recalls Food frequency questionnaire
33 Correlations of Sodium with Indices of Completeness Diet Studies: Correlation of sodium and calorie 0.80 in NHANES in PREMIER 2 trial Urine Studies: Correlations of Sodium with creatinine excretion 0.56 in PREMIER 2 trial 1 Dietary Guidelines Scientific Advisory Committee, Unpublished
34 CVD Risk Random Error in Na Measurement Attenuates the Relationship of Na Intake on CVD Risk Sodium Intake Actual Impact of Random Error
35 CVD Risk Random Error in Na Measurement Attenuates the Relationship of Na Intake on CVD Risk Sodium Intake Actual Impact of Random Error
36 CVD Risk Systematic Error in Na Measurement Attenuates the Relationship of Na Intake on CVD Risk Sodium Intake Actual Impact of Systematic Error
37 CVD Risk Systematic Error in Na Measurement Could Lead to J-Shaped or Inverse Relationship of Na Intake with CVD Risk Sodium Intake Actual Potential Impact of Systematic Error
38
39 Observational Study with Systematic Error in Na Assessment: NHANES II
40 Hazard Ratio (HR) Case of Systematic Error Leading to Bias: Increased CVD Mortality in Persons with Lowest Na (by Quartile of Na Intake in mg/d) P=0.03 Q1 vs Q Cohen, JGIM 2008;23: st 2nd 3rd 4th Na Quartile of based on mg of Na/d
41 Evidence of Contamination in a Cohort Study 1 (NHANESIII) Reporting Increased Mortality in Persons with Low Sodium Intake on 24Hr Dietary Recall Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 1 Cohen, JGIM 2008;23:
42 Evidence of Contamination in a Cohort Study 1 (NHANESIII) Reporting Increased Mortality in Persons with Low Sodium Intake on 24Hr Dietary Recall Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 Energy Intake (kcal) 1,282 1,762 2,152 2,938 1 Cohen, JGIM 2008;23:
43 Evidence of Contamination Evidence in a Cohort of Massive Study 1 (NHANESIII) Reporting Underreporting Increased Mortality of Calorie in Persons Intake with Low Sodium Intake Leading on 24Hr to Systematic Dietary Recall Error in Estimate or Sodium Intake Quartile of Sodium Intake: 1 st (Lowest) 2nd 3rd 4 th (Highest) Na (mg/d) 1,501 2,483 3,441 5,497 Energy Intake (kcal) 1,282 1,762 2,152 2,938 BMI (kg/m 2 ) Cohen, JGIM 2008;23:
44 Hazard Ratio (HR) Reduced Systematic Error from Use of Na/Kcal Ratio as Exposure instead of Na/d P=0.26 Q1 vs Q Cohen, JGIM 2008;23: st 2nd 3rd 4th Na Quartile of based on mg of Na /Kcal
45 J-Shaped Relationship of Total Mortality with Urine Sodium Excretion in Patients with Type 1 Diabetes Extremely low levels are most likely the result of extreme undercollection Thomas, Diabetes Care 2011: 861-6
46 Example of Low Sodium Excretion Related to Under-collection 78 year old women, screened for a trial No special diet 172 pounds, 5 2, BMI 31 kg/m 2 Two 24 hour urine collections required Detailed instructions provided Urine Lab Range 1st 2nd Sodium (mmol/24hr) Volume (ml/24hr) Creatinine (g/24 hr).63 to
47 Arguments Made by Those who Oppose Sodium Reduction Clinical trial of sodium reduction with hard clinical outcomes is needed Only salt sensitive persons should reduce their salt intake Such trials are impossible because of logistical, financial and ethical considerations. No test available. Irrelevant given the massive scope of the blood pressure epidemic. Extremely unlikely: 1) major methodological limitations of cohort studies + 2) overinterpretation of biomarkers Sodium reduction might be harmful
48 Trials of Sodium Reduction in Participants Heart Failure by Paterna Hospitalized NYHA Class III Heart Failure Intensive medication regimens 100% ACEI 100% Lasix 85% Spironolactone Medical management Unconventional, leading to untreated longterm volume depletion Paterna, Am J Card 2009:103:93 Paterna, Am J Med Science 2011, 342: 27
49 No Effect of Reducing Sodium Intake on LDL Cholesterol Typical Diet LDL-C mmol/l P= P=0.9 DASH Diet Harsha, Hypertension 2004;43;393 1,500 2,400 3,300 Sodium Level: mg/d per day
50 Key Points to Remember The estimated benefits of sodium reduction are substantial and warrant major public health efforts to reduce salt intake Major methodological issues limit the usefulness of available cohort studies as a basis for guiding policy, much less reversing recommendations
The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss?
The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss? CIA-Harvard Menus of Change National Leadership Summit June 10, 2014 Cambridge, MA General Session IV Lawrence J Appel, MD,
Sodium and Health: Evidence, Policy, Reality
Sodium and Health: Evidence, Policy, Reality Cheryl A. M. Anderson, PhD, MPH, MS University of California San Diego Department of Family Medicine and Public Health Email: c1anderson@ucsd.edu Sodium Intake
Disclaimer for sharing or use of any of this presentation
Disclaimer for sharing or use of any of this presentation If you share or use this presentation, any parts of it, or any of the info in it is used, please ensure you always credit the Ohio Cardiovascular
The Need for Balance in Evaluating the Evidence on Na and CVD
The Need for Balance in Evaluating the Evidence on Na and CVD Salim Yusuf Professor of Medicine, McMaster University Executive Director, Population Health Research Institute Vice-President Research, Hamilton
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
Why you should take the latest sodium study with a huge grain of salt
Harvard School of Public Health The Nutrition Source Flawed Science on Sodium from JAMA Why you should take the latest sodium study with a huge grain of salt A new study would have you believe that low-salt
Salt reduction - benefits beyond blood pressure
Salt reduction - benefits beyond blood pressure Jennifer Keogh Associate Professor Sansom Institute for Health Research University of South Australia Intersalt study 1 Epidemiological study of electrolyte
What s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
Sodium and Potassium Intake and Cardiovascular and Bone Health:
Sodium and Potassium Intake and Cardiovascular and Bone Health: How Important is the Ratio? Connie M. Weaver Nutrition Science Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter
MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
Hypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
Update in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
HYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
ADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
Objectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
Hypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
IS IT TIME TO REDUCE SALT IN SOUTH AFRICAN FOOD? KRISELA STEYN DEPT OF MEDICINE, UCT CHRONIC DISEASES INITIATIVE IN AFRICA
IS IT TIME TO REDUCE SALT IN SOUTH AFRICAN FOOD? KRISELA STEYN DEPT OF MEDICINE, UCT CHRONIC DISEASES INITIATIVE IN AFRICA INTERSALT STUDY OBSERVATIONAL STUDY IN 52 COUNTRIES CONDUCTED IN THE 1980s 10
Interventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
Risk Factors for Heart Disease
Developmental Perspectives on Health Disparities from Conception Through Adulthood Risk Factors for Heart Disease Philip Greenland, MD Harry W. Dingman Professor Chair, Department of Preventive Medicine
Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
Using the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
Cardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N
NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N OBJECTIVES List controversial points from the current Dietary Guidelines for Americans (DGA). Recognize the policy
In almost every country that has established guidelines for
AHA Presidential Advisory Sodium, Blood Pressure, and Cardiovascular Disease Further Evidence Supporting the American Heart Association Sodium Reduction Recommendations Paul K. Whelton, MB, MD, MSc, FAHA,
Hypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
Diabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
Vascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
ADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
Treating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
Modern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
Placebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
Blood Pressure Measurement in SPRINT
Blood Pressure Measurement in SPRINT Karen C. Johnson, MD, MPH, FAHA Vice Chair, SPRINT Steering Committee University of Tennessee Health Science Center, Department of Preventive Medicine For the SPRINT
Managing Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
T. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Disclosure No competing interest to declare about this
Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) 1 3
Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) 1 3 Kay-Tee Khaw, Sheila Bingham, Ailsa Welch, Robert Luben,
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
Project Summary: Draft Proposal Continued RESULTS. on the DASH Diet and 30 of the 40 original subjects on the Pro-DASH Diet.
Project Summary: Draft Proposal Continued RESULTS Subjects The HNFE 3034 Spring 2013 semester s research study included 34 of the 38 original subjects on the DASH Diet and 30 of the 40 original subjects
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women (Lancet. 2017 Mar 25;389(10075):1229-1237) 1 Silvia STRINGHINI Senior
Management of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
Blood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
Systolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
Fructose, Uric Acid and Hypertension in Children and Adolescents
Fructose, Uric Acid and Hypertension in Children and Adolescents Daniel I. Feig, MD, PhD, MS Director, Division of Nephrology Department of Pediatrics University of Alabama, Birmingham Topics for Discussion
Recent Hypertension Guidelines
Recent Hypertension Guidelines Lawrence J. Fine, MD, DrPH, FAHA Division of Cardiovascular Sciences NHLBI/NIH February 19, 2014 Disclosures: Member of Panel Appointed to the Eighth Joint National Committee
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
Primary Physiological
Appendix Table 3. Primary outcomes and effect sizes for trials included in review. Trial Behavior Outcome Effect size Group difference in original units Primary Physiological ACT 22, a Be Fit, Be Well
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
The Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
Egyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
Management of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
The prevalence of hypertension in a representative
CLINICAL STRATEGIES FOR OPTIMAL HYPERTENSION MANAGEMENT Roger S. Blumenthal, MD * ABSTRACT In the United States, approximately 25% of the adult population older than 40 years has hypertension. Americans
Current CDC Efforts Concerning Sodium Intake
Current CDC Efforts Concerning Sodium Intake Robert K. Merritt Chief & Supervisory Health Scientist Epidemiology & Surveillance Branch Division for Heart Disease and Stroke Prevention National Center for
Preventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC
UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC DISCLOSURES: I have no conflict-of-interest disclosures UPDATES: THE STRUGGLE
Modern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
Optimizing Postpartum Maternal Health to Prevent Chronic Diseases
Optimizing Postpartum Maternal Health to Prevent Chronic Diseases Amy Loden, MD, FACP, NCMP Disclosures Research: None Financial: none applicable to this presentation PRIUM QEssentials Market Research
Jared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
Blood Pressure Acre Surgery Diviash Thakrar
Blood Pressure Acre Surgery Diviash Thakrar Why Are We Doing This? 1. Improve education for patients within the practice 2. Allow us use this for general health promotion Raise money for charity 3. Raise
Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016
The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
Economically efficient approaches to address chronic disease in developing countries
Economically efficient approaches to address chronic disease in developing countries Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Brigham & Women s Hospital Harvard Medical School Center
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
Role of Minerals in Hypertension
Role of Minerals in Hypertension Lecture objectives By the end of the lecture students will be able to Define primary and secondary hypertention and their risk factors. Relate role of minerals with hypertention.
w High Blood Pressure Guidelines Create New At-Risk Classification
Journal of Cardiovascular Nursing Vol. 19, No. 6, pp 357-371 2004 LippincoltWilliams SWilkins, Inc. w High Blood Pressure Guidelines Create New At-Risk Classification Changes in Blood Pressure Classification
40% minimum reduction from
160 Circulatory Disease Mortality Target: Death rates in England 1993-2006 Persons under 75 Death / 100,000 population A fall of 44% over 10 years 140 120 100 80 60 40 20 141.0 84.2 Immortality guaranteed
Salt: How much less should we eat for health? Understanding the recent IOM report
Salt: How much less should we eat for health? Understanding the recent IOM report We should all eat less salt but how much less? 1500 milligrams a day has been recommended as a target but the US Institute
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
Hypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
Marginal donors: Young vs. Old
Marginal donors: Young vs. Old Why we should prefer older donors Geir Mjøen, Oslo, Norway Long term risks in kidney donors Interpretation Consequences Recommendation Kidney donors Donors are healthy at
Causes of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
2009 Shattuck Lecture
2009 Shattuck Lecture The Hypertension Paradox: Remarkable Advances in Therapy but Continued Increase in Prevalence of Uncontrolled Hypertension Disclosures: Dr. Chobanian has no conflicts to disclose
Hypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center
Adolescent Hypertension Roles of obesity and hyperuricemia Daniel Landau, MD Pediatrics, Soroka University Medical Center Blood Pressure Tables BP standards based on sex, age, and height provide a precise
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
What is hypertension?
HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England
The effect of a change in ambient temperature on blood pressure in normotensives
(2001) 15, 113 117 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE The effect of a change in ambient temperature on blood pressure in normotensives
Diabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
Changing the Food Environment to Reduce Cardiovascular Disease Risk
Changing the Food Environment to Reduce Cardiovascular Disease Risk March 10, 2009 Christine Johnson Nutrition Policy Manager Cardiovascular Disease Prevention and Control Program NYC Department of Health
Managing HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None
MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH None 1 Objectives Why the need for change in the guidelines? What is the potential impact of these guidelines? Where do we go from here?